Head-To-Head Review: Procter & Gamble (NYSE:PG) and Kenvue (NYSE:KVUE)

Procter & Gamble (NYSE:PG – Get Free Report) and Kenvue (NYSE:KVUE – Get Free Report) are both large-cap consumer staples companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, analyst recommendations and risk.

Volatility & Risk

Procter & Gamble has a beta of 0.36, suggesting that its stock price is 64% less volatile than the S&P 500. Comparatively, Kenvue has a beta of 0.48, suggesting that its stock price is 52% less volatile than the S&P 500.

Dividends

Procter & Gamble pays an annual dividend of $4.35 per share and has a dividend yield of 2.5%. Kenvue pays an annual dividend of $0.84 per share and has a dividend yield of 4.4%. Procter & Gamble pays out 65.5% of its earnings in the form of a dividend. Kenvue pays out 95.5% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Procter & Gamble has raised its dividend for 70 consecutive years and Kenvue has raised its dividend for 1 consecutive years.

Analyst Ratings

This is a summary of current recommendations and price targets for Procter & Gamble and Kenvue, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Procter & Gamble 0 11 15 0 2.58
Kenvue 0 10 0 0 2.00

Procter & Gamble presently has a consensus price target of $170.57, suggesting a potential downside of 1.41%. Kenvue has a consensus price target of $19.29, suggesting a potential downside of 0.13%. Given Kenvue’s higher probable upside, analysts clearly believe Kenvue is more favorable than Procter & Gamble.

Valuation & Earnings

This table compares Procter & Gamble and Kenvue”s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Procter & Gamble $87.92 billion 4.56 $16.05 billion $6.64 26.06
Kenvue $15.53 billion 2.39 $1.47 billion $0.88 21.94

Procter & Gamble has higher revenue and earnings than Kenvue. Kenvue is trading at a lower price-to-earnings ratio than Procter & Gamble, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Procter & Gamble and Kenvue’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Procter & Gamble 18.23% 31.02% 12.92%
Kenvue 10.76% 21.22% 8.37%

Insider & Institutional Ownership

65.8% of Procter & Gamble shares are held by institutional investors. Comparatively, 97.6% of Kenvue shares are held by institutional investors. 0.2% of Procter & Gamble shares are held by company insiders. Comparatively, 1.6% of Kenvue shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Procter & Gamble beats Kenvue on 12 of the 17 factors compared between the two stocks.

About Procter & Gamble

(Get Free Report)

The Procter & Gamble Company is a consumer goods company that develops, manufactures and markets products for everyday use. Founded in 1837 by William Procter and James Gamble, the company is headquartered in Cincinnati, Ohio. Its products span beauty, grooming, health care, fabric and home care, and baby, feminine and family care. Well-known brands include Tide, Pampers, Gillette, Pantene, Olay, Oral-B, Crest, Dawn, Charmin and Bounty. Procter & Gamble sells its products in markets around the world through retail stores, e-commerce platforms and other distribution channels.

About Kenvue

(Get Free Report)

Kenvue Inc. is a consumer health company that develops and sells products for everyday health and personal care. Its portfolio includes over-the-counter medicines, skin and hair care, oral care, wound care, and baby care products. Its well-known brands include Tylenol, Neutrogena, Aveeno, Listerine, Band-Aid, Johnson’s, and Zyrtec. Kenvue organizes its business around Self Care, Skin Health and Beauty, and Essential Health. The company became an independent business in 2023 after Johnson & Johnson completed the separation of its consumer health business.

Receive News & Ratings for Procter & Gamble Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Procter & Gamble and related companies with MarketBeat.com's FREE daily email newsletter.